Summit Therapeutics Quarterly Income Statement
NASDAQ: SMMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
17.59+0.42 (+2.45%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Summit Therapeutics revenue and earnings
Summit Therapeutics reported a net loss of $215.7 million, compared with a loss of $565.7 million a year earlier. Diluted earnings per share came in at -$0.28.
Summary generated from market data by MetaCap's automated system. Methodology
Summit Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | 0 | 0 | — | — | 0 | 0 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | -100.00% |
| Operating Expenses | 220.50M | 195.21M | 224.93M | 234.21M | 568.44M | 66.85M | 65.61M | 58.38M | 59.62M | 42.39M | 35.39M | 20.76M |
| Research & Development | 157.73M | 132.62M | 147.29M | 131.10M | 208.02M | 51.27M | 51.38M | 37.72M | 30.80M | 30.87M | 24.81M | 15.32M |
| Operating Income | — | — | — | — | — | — | -65.61M | -58.38M | -59.62M | -42.39M | -36.21M | -20.49M |
| Interest Expense | — | — | 0 | 0 | 0 | 0 | 9.00K | 2.45M | 3.10M | 3.12M | 2.90M | 2.72M |
| Other Income (Expense) | 4.80M | 5.79M | 5.75M | 2.42M | 2.73M | 3.94M | 4.42M | 4.58M | 2.33M | 2.04M | 16.10M | -776.00K |
| Net Income | -215.70M | -189.42M | -219.17M | -231.79M | -565.71M | -62.91M | -61.20M | -56.25M | -60.38M | -43.47M | -36.57M | -21.27M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.28 | -0.24 | -0.28 | -0.31 | -0.76 | -0.09 | -0.08 | -0.08 | -0.09 | -0.06 | 0.49 | -0.03 |
| EPS (Diluted) | -0.28 | -0.24 | -0.28 | -0.31 | -0.76 | -0.09 | -0.08 | -0.08 | -0.09 | -0.06 | 0.49 | -0.03 |
| Shares Outstanding (Basic) | 778.18M | 775.46M | — | 743.42M | 742.62M | 738.08M | — | 726.66M | 707.90M | 701.79M | — | 697.74M |
| Shares Outstanding (Diluted) | 778.18M | 775.46M | — | 743.42M | 742.62M | 738.08M | — | 726.66M | 707.90M | 701.79M | — | 697.74M |
| EBITDA | — | — | — | — | — | — | -65.59M | -58.36M | -59.60M | -42.36M | -36.18M | -20.46M |
This table shows 12 quarterly periods of Summit Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow SMMT's reporting calendar. What is a income statement?